×
About 28,546 results

ALLMedicine™ Metastatic Breast Cancer Center

Research & Reviews  12,457 results

The challenge of value-based pricing in combination therapy: the case of trastuzumab an...
https://doi.org/10.1080/14737167.2021.1896968
Expert Review of Pharmacoeconomics & Outcomes Research; Jiao B, Garrison L

Mar 1st, 2021 - Under current reimbursement (CR) practice even though an add-on drug in a combination therapy may produce marginal value in terms of health gain, the original therapy may also share in the reward for this additional value. We examine an alternativ...

A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer.
https://doi.org/10.1177/1060028021998320
The Annals of Pharmacotherapy; Nguyen X, Hooper M et. al.

Feb 25th, 2021 - To review the pharmacology, efficacy, and safety of antibody-drug conjugate fam-trastuzumab deruxtecan-nxki in the treatment of advanced, unresectable, or metastatic breast cancer. Relevant information was identified through a MEDLINE/PubMed (Janu...

A case of pembrolizumab-induced fulminant Type 1 diabetes mellitus in breast cancer.
https://doi.org/10.2217/imt-2020-0222
Immunotherapy Tang Y, Zhao Z et. al.

Feb 25th, 2021 - Aim: The programmed cell death protein-1 (PD-1) inhibitor, pembrolizumab, can exert anti-tumor effects and induce immune-related adverse events. Here, we for the first time describe a patient with metastatic breast cancer who developed fulminant T...

Alpelisib for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative...
https://doi.org/10.1080/14656566.2021.1873952
Expert Opinion on Pharmacotherapy; Leenhardt F, Alexandre M et. al.

Feb 24th, 2021 - Introduction: Two-thirds of advanced breast cancers are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-). Gene mutations in PIK3CA, encoding the PI3K catalytic subunit alpha of phosphatidyl-in...

see more →

Guidelines  195 results

ESMO Guideline for Cancer Patient Management During the COVID-19 Pandemic
https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic?hit=ehp

Sep 17th, 2020 - These recommendations should be used as guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of cancer patients. The situation is evolving, and pragmatic ...

Differential risk of incident cancer in patients with heart failure: A nationwide population-based cohort study
https://www.journal-of-cardiology.com/article/S0914-5087(20)30271-9/fulltext
Journal of Cardiology; Kwak S

Aug 25th, 2020 - Patients with heart failure (HF) are more at risk of developing cancer than the general population.

ECOG-ACRIN Trial Reassures Clinicians, Patients That Locoregional Therapy Is Not Beneficial for Stage IV Metastatic Breast Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200218/full/

Jun 23rd, 2020 - For patients with stage IV metastatic breast cancer and an intact primary tumor (ITP), the early initiation of locoregional treatment (LRT) was not associated with longer survival or improvements in health-related quality of life (HRQoL) compared ...

see more →

Drugs  395 results see all →

Clinicaltrials.gov  14,253 results

The challenge of value-based pricing in combination therapy: the case of trastuzumab an...
https://doi.org/10.1080/14737167.2021.1896968
Expert Review of Pharmacoeconomics & Outcomes Research; Jiao B, Garrison L

Mar 1st, 2021 - Under current reimbursement (CR) practice even though an add-on drug in a combination therapy may produce marginal value in terms of health gain, the original therapy may also share in the reward for this additional value. We examine an alternativ...

A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer.
https://doi.org/10.1177/1060028021998320
The Annals of Pharmacotherapy; Nguyen X, Hooper M et. al.

Feb 25th, 2021 - To review the pharmacology, efficacy, and safety of antibody-drug conjugate fam-trastuzumab deruxtecan-nxki in the treatment of advanced, unresectable, or metastatic breast cancer. Relevant information was identified through a MEDLINE/PubMed (Janu...

A case of pembrolizumab-induced fulminant Type 1 diabetes mellitus in breast cancer.
https://doi.org/10.2217/imt-2020-0222
Immunotherapy Tang Y, Zhao Z et. al.

Feb 25th, 2021 - Aim: The programmed cell death protein-1 (PD-1) inhibitor, pembrolizumab, can exert anti-tumor effects and induce immune-related adverse events. Here, we for the first time describe a patient with metastatic breast cancer who developed fulminant T...

How Has COVID-19 Affected Metastatic Breast Cancer Treatment Decisions?
https://www.medscape.com/viewarticle/946340

Feb 25th, 2021 - Patients with metastatic breast cancer (MBC) face an elevated risk of severe illness or dying from COVID-19. Given the slow rollout of the Moderna and Pfizer COVID vaccines and new, more infectious viral variants circulating in the United States, ...

see more →

News  1,221 results

How Has COVID-19 Affected Metastatic Breast Cancer Treatment Decisions?
https://www.medscape.com/viewarticle/946340

Feb 25th, 2021 - Patients with metastatic breast cancer (MBC) face an elevated risk of severe illness or dying from COVID-19. Given the slow rollout of the Moderna and Pfizer COVID vaccines and new, more infectious viral variants circulating in the United States, ...

Obesity 'Clearly' Not Tied to Worse Survival in MBC
https://www.medscape.com/viewarticle/944913

Jan 28th, 2021 - The relationship between obesity and overweight and breast cancer has some elements of mystery. But this is not one of them: in metastatic breast cancer (MBC), excess body weight does not negatively influence outcomes. Multiple small studies have ...

Margetuximab for HER2+ Metastatic Breast Cancer Falls Short
https://www.medscape.com/viewarticle/943233

Jan 6th, 2021 - This transcript has been edited for clarity. Happy holidays, everyone. This is Dr Kathy Miller from Indiana University. I want to make sure you've had a chance to think carefully about the margetuximab approval by the US Food and Drug Administrati...

CONTESSA: Oral Taxane Meets Primary Endpoint
https://www.medscape.com/viewarticle/943090

Jan 5th, 2021 - This transcript has been edited for clarity. Hi. It's Dr Kathy Miller with more exciting news from the San Antonio Breast Cancer Symposium. I'm talking about the use of oral taxane therapy. You all know that the taxanes are a mainstay of our treat...

Margetuximab Approved for HER2+ Metastatic Breast Cancer
https://www.medscape.com/viewarticle/942869

Dec 16th, 2020 - A new monoclonal antibody that targets HER2+ in breast cancer, margetuximab-cmkb (Margenza), has been approved by the Food and Drug Administration (FDA). The new drug is indicated for use in combination with chemotherapy for the treatment of patie...

see more →

Patient Education  25 results see all →